Epilepsy-pregnancy registries: An update.

IF 6.6 1区 医学 Q1 CLINICAL NEUROLOGY
Epilepsia Pub Date : 2024-11-14 DOI:10.1111/epi.18180
Piero Perucca, Dina Battino, Rebecca Bromley, Lei Chen, John Craig, Sonia Hernandez-Diaz, Lewis B Holmes, Kiren G Koshy, Kimford J Meador, Ramshekhar N Menon, Terence J O'Brien, Page B Pennell, Dong Zhou, Torbjörn Tomson
{"title":"Epilepsy-pregnancy registries: An update.","authors":"Piero Perucca, Dina Battino, Rebecca Bromley, Lei Chen, John Craig, Sonia Hernandez-Diaz, Lewis B Holmes, Kiren G Koshy, Kimford J Meador, Ramshekhar N Menon, Terence J O'Brien, Page B Pennell, Dong Zhou, Torbjörn Tomson","doi":"10.1111/epi.18180","DOIUrl":null,"url":null,"abstract":"<p><p>This report is the first comprehensive update on the activities of existing epilepsy-pregnancy registries since 2010. The primary aim of these registries, which were initiated by independent international research groups some 25 years ago, has been to assess the risk of major congenital malformations (MCMs) in offspring exposed in utero to different antiseizure medications (ASMs). Progress reports are provided here from the five original registries (the International Registry of Antiepileptic Drugs and Pregnancy EURAP, the North American Antiepileptic Drug Pregnancy Registry, the UK and Ireland Epilepsy and Pregnancy Register, the Kerala Registry of Epilepsy and Pregnancy, and the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs) plus the more recently initiated West China Registry. Since their inception, the registries have published a wealth of data revealing important differences in risks across the most frequently used ASM treatments, thereby facilitating rational management of women with epilepsy who are of childbearing potential. Although the number of pregnancies enrolled in the different registries has more than doubled since the 2010 report, many questions remain. These include outcomes following prenatal exposure to most of the newer ASMs or different ASM combinations, as well as associations with specific MCMs rather than MCMs as a collective. All the registries, therefore, remain active and continue to enroll pregnancies. Administrative health care databases have been utilized more recently for the assessment of MCM risks and other adverse pregnancy outcomes associated with in utero exposure to ASMs. Although these can provide population-based complementary information, they cannot replace the specific epilepsy-pregnancy registries with their more detailed validated individual information. Given the multiple newer ASMs that are increasingly used and the continuing multiple knowledge gaps for the older ASMs, epilepsy-pregnancy registries will continue to play an important role in the future.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/epi.18180","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This report is the first comprehensive update on the activities of existing epilepsy-pregnancy registries since 2010. The primary aim of these registries, which were initiated by independent international research groups some 25 years ago, has been to assess the risk of major congenital malformations (MCMs) in offspring exposed in utero to different antiseizure medications (ASMs). Progress reports are provided here from the five original registries (the International Registry of Antiepileptic Drugs and Pregnancy EURAP, the North American Antiepileptic Drug Pregnancy Registry, the UK and Ireland Epilepsy and Pregnancy Register, the Kerala Registry of Epilepsy and Pregnancy, and the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs) plus the more recently initiated West China Registry. Since their inception, the registries have published a wealth of data revealing important differences in risks across the most frequently used ASM treatments, thereby facilitating rational management of women with epilepsy who are of childbearing potential. Although the number of pregnancies enrolled in the different registries has more than doubled since the 2010 report, many questions remain. These include outcomes following prenatal exposure to most of the newer ASMs or different ASM combinations, as well as associations with specific MCMs rather than MCMs as a collective. All the registries, therefore, remain active and continue to enroll pregnancies. Administrative health care databases have been utilized more recently for the assessment of MCM risks and other adverse pregnancy outcomes associated with in utero exposure to ASMs. Although these can provide population-based complementary information, they cannot replace the specific epilepsy-pregnancy registries with their more detailed validated individual information. Given the multiple newer ASMs that are increasingly used and the continuing multiple knowledge gaps for the older ASMs, epilepsy-pregnancy registries will continue to play an important role in the future.

癫痫-怀孕登记:更新。
本报告是自 2010 年以来对现有癫痫-怀孕登记活动的首次全面更新。这些登记项目由独立的国际研究小组在大约 25 年前发起,其主要目的是评估子宫内暴露于不同抗癫痫药物 (ASM) 的后代发生重大先天畸形 (MCM) 的风险。本文提供了五个原始登记处(国际抗癫痫药物和妊娠登记处 EURAP、北美抗癫痫药物妊娠登记处、英国和爱尔兰癫痫和妊娠登记处、喀拉拉邦癫痫和妊娠登记处、拉乌尔-沃伦贝格澳大利亚抗癫痫药物妊娠登记处)以及最近启动的中国西部登记处的进展报告。自成立以来,这些登记处已公布了大量数据,揭示了最常用的 ASM 治疗在风险方面的重要差异,从而促进了对有生育能力的女性癫痫患者的合理管理。尽管自 2010 年报告发布以来,不同登记处登记的妊娠数量增加了一倍多,但许多问题依然存在。这些问题包括产前暴露于大多数较新的 ASM 或不同 ASM 组合后的结果,以及与特定 MCMs 而非 MCMs 整体的关联。因此,所有登记处都保持活跃,并继续登记孕妇。最近,人们开始利用行政医疗保健数据库来评估与子宫内接触 ASM 相关的含甲状腺激素风险和其他不良妊娠结局。虽然这些数据库可以提供基于人群的补充信息,但它们无法取代特定的癫痫-妊娠登记册及其更详细的经过验证的个体信息。鉴于越来越多地使用多种较新的 ASM,而对较老的 ASM 仍存在多种知识缺口,癫痫-怀孕登记册在未来将继续发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia
Epilepsia 医学-临床神经学
CiteScore
10.90
自引率
10.70%
发文量
319
审稿时长
2-4 weeks
期刊介绍: Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信